A multi-institutional real world data study from India of 3453 non-metastatic breast cancer patients undergoing upfront surgery
| Autor: | Selvi Radhakrishna, Kapil Kumar, Ajay Kumar Dewan, Juhi Tayal, Renu Iyer Kashinath, Dinesh Chandra Doval, Naga Amulya Mullapudi, Sudeep Gupta, Anurag Mehta, Vineet Talwar, Harit Chaturvedi, Rupal Tripathi, Ullas Batra, Ramesh B. V. Nimmagadda |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Oncology medicine.medical_specialty Future studies India lcsh:Medicine Breast Neoplasms Triple Negative Breast Neoplasms Mastectomy Segmental Disease-Free Survival Article Young Adult 03 medical and health sciences Breast cancer Cancer epidemiology 0302 clinical medicine Internal medicine medicine Humans Non metastatic 030212 general & internal medicine lcsh:Science Pathological Mastectomy Aged Neoplasm Staging Retrospective Studies Aged 80 and over Multidisciplinary business.industry lcsh:R Middle Aged medicine.disease Survival Analysis Hormone receptor Lymphatic Metastasis 030220 oncology & carcinogenesis Cohort Curative surgery Female lcsh:Q business Real world data |
| Zdroj: | Scientific Reports, Vol 10, Iss 1, Pp 1-10 (2020) Scientific Reports |
| ISSN: | 2045-2322 |
| DOI: | 10.1038/s41598-020-62618-3 |
| Popis: | The present analysis reports the clinical, pathological, treatment profile and overall survival (OS) and disease-free survival (DFS) outcomes of consecutive breast cancer patients from three Indian centres, who underwent curative surgery as their first treatment. Among the 3453 patients, stage I, II, and III cases were 11.75%, 66.79%, and 21.64%, respectively while hormone receptor positive/HER2 negative, triple negative (TNBC) and hormone receptor any/HER2 positive cases were 55.2%, 24.2% and 20.6%, respectively. The five-year OS in the entire cohort, node-negative and node-positive patients were 94.1% (93.25–94.98), 96.17% (95.2–97.15) and 91.83% (90.36–93.31), respectively, and the corresponding DFS were 88.1% (86.96–89.31), 92.0% (90.64–93.39) and 83.93% (82.03–85.89), respectively. The five-year OS in hormone receptor positive/HER2 negative, TNBC and HER2 subgroups were 96.11% (95.12–97.1), 92.74% (90.73–94.8) and 90.62% (88.17–93.15), respectively, and the corresponding DFS were 91.59% (90.19–93.02), 85.46% (82.79–88.22) and 81.29% (78.11–84.61), respectively. This is the largest dataset of early breast cancer patients from India with survival outcome analysis and can therefore serve as a benchmark for future studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|